NVO stock: buy or sell?
May 26th, 2020
Novo Nordisk A\u002FS, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide.
Should I buy NVO stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Novo Nordisk A/S stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Novo Nordisk A/S stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for NVO stock for the last 30 days.
NVO stock analysis
After several days of continuous hikes in past weeks, Novo Nordisk A/S eased -2.21% to $63.40.
After several days of continuous rises in past weeks, Novo Nordisk A/S eased -2.21% to $63.40. Since price and SMA200d lines crossed up on March, NVO climbed $11.11 (21.25%). In the last 4 days when SMA50d and SMA100d crossed up, NVO price slipped $-1.42 per share (-2.19%). On Wednesday, NVO hit a new all time high, pushing higher than on Apr/28 tops. Check different trading setups that use ATHs as triggers.
Novo Nordisk A/S declined a tragic -2.21% this week.
Not so far away is the last all-time high Novo Nordisk A/S marked last week. Since late March when NVO stock price broke up the SMA40w line, it gained $14.62 (29.97%). Since SMA10w and SMA20w crossed up last week, NVO price slid a -0.80%.
NVO stock price history
NVO stock went public on April 28th, 1992 with a price of $0.011. Since then, NVO stock grew a 633,900.00%, with an average of 22,639.30% per year. If you had invested right after NVO's IPO a $1,000 in NVO stock in 1992, it would worth $6,339,000.00 today.
1: Adjusted price after possible price splits or reverse-splits.
NVO stock historical price chart
NVO stock reached all-time highs on Wednesday with a price of $66.02.
NVO stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price target for Novo Nordisk A/S stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Novo Nordisk A/S missed the estimates of the experts and posted a bad EPS of $0.54 per share when experts were expecting $0.57.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a neutral movement of 0.12% to $111,831.00 M dollars. Similarly, its income margin (compared to sales) stayed steady to 34.54%, that is $38,628.00 million.
|2013||$83,570 M||-||$25,180 M30.1%||-|
|2014||$14,427 M||-82.74%||$4,302 M29.8%||-82.92%|
|2015||$107,927 M||648.09%||$34,860 M32.3%||710.33%|
|2016||$111,780 M||3.57%||$37,925 M33.9%||8.79%|
|2017||$111,696 M||-0.08%||$38,130 M34.1%||0.54%|
|2018||$111,831 M||0.12%||$38,628 M34.5%||1.31%|
Quarterly financial resultsNovo Nordisk A/S posted $29,732.00 M in sales for 2018-Q4, a 7.10% up compared to previous quarter. Reported quarter income marked $8,497.00 M with a profit margin of 28.58%. Profit margin slightly fell a -3.97% compared to previous quarter when profit margin was 32.55%. When comparing sales to same quarter last year, Novo Nordisk A/S sales marked an outstanding increase and rocketed a 559.07%. Looking back to recent quarterly results, Novo Nordisk A/S posted 5 negative quarters in a row.
|2017-Q1||$28,450 M||-||$10,160 M35.7%||-|
|2017-Q2||$28,640 M||0.67%||$9,950 M34.7%||-2.07%|
|2017-Q3||$4,200 M||-85.34%||$1,542 M36.7%||-84.51%|
|2017-Q4||$4,511 M||7.42%||$1,330 M29.5%||-13.73%|
|2018-Q1||$26,930 M||496.96%||$10,751 M39.9%||708.32%|
|2018-Q2||$27,407 M||1.77%||$10,343 M37.7%||-3.79%|
|2018-Q3||$27,762 M||1.30%||$9,037 M32.6%||-12.63%|
|2018-Q4||$29,732 M||7.10%||$8,497 M28.6%||-5.98%|
Novo Nordisk A/S ownershipHaving a look at Novo Nordisk A/S ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Novo Nordisk A/S, 0.01% of all outstanding shares are owned by its staff.
In case of Novo Nordisk A/S stock, 9.48% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVO stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$148.4 B|
|Total shares||2,340.0 M|
|Float shares||1,670.0 M|
|- Institutional holdings (%)||9.5%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Tuesday, May 26th, 2020|
|Day range||$63.34 - $64.61|
|Average true range||$1.23|
|50d mov avg||$60.46|
|100d mov avg||$60.23|
|200d mov avg||$56.74|
Novo Nordisk A/S performanceTo better understand Novo Nordisk A/S performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Novo Nordisk A/S against in the following table:
Novo Nordisk A/S competitorsUnfortunately, we could not find any public company that could be defined as Novo Nordisk A/S competitor. This doesn't mean Novo Nordisk A/S does not have any competitor in the market, it's just we could not detected it.
Latest NVO stock news
- Seeking AlphaNovo Nordisk's Oral Diabetes Drug Is A Force To Be Reckoned WithAugust 22, 2018
- Seeking AlphaNovo Nordisk: Obesity Crisis Continues To Get Worse - Buy The Stock TodayJune 3, 2018